DaVita Inc.

111.72+1.87+1.70%Vol 132.32K1Y Perf 45.44%
Apr 16th, 2021 10:42 DELAYED
BID111.63 ASK111.70
Open110.44 Previous Close109.85
Pre-Market- After-Market-
 - -%  - -
Target Price
132.67 
Analyst Rating
Moderate Buy 2.25
Potential %
18.99 
Finscreener Ranking
★+     43.52
Insiders Trans % 3/6/12 mo.
-100/-100/-82 
Value Ranking
★★+     48.70
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     53.99
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap12.22B 
Earnings Rating
Sell
Price Range Ratio 52W %
74.69 
Earnings Date
4th May 2021

Today's Price Range

110.10111.83

52W Range

71.70125.28

5 Year PE Ratio Range

11.8089.60

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
0.78%
1 Month
2.05%
3 Months
-7.49%
6 Months
21.01%
1 Year
45.44%
3 Years
73.90%
5 Years
48.03%
10 Years
152.41%

TickerPriceChg.Chg.%
DVA111.721.87001.70
AAPL134.28-0.2200-0.16
GOOG2 290.23-6.4300-0.28
MSFT259.42-0.0800-0.03
XOM56.85-0.1300-0.23
WFC43.341.10002.60
JNJ160.830.44000.27
FB305.70-2.1200-0.69
GE13.49-0.0600-0.44
JPM154.081.91001.26
Financial StrengthValueIndustryS&P 500US Markets
1.10
1.30
0.89
8.09
5.30
Leverage Ratio 10.20
ProfitabilityValueIndustryS&P 500US Markets
27.60
14.00
19.50
10.80
8.04
RevenueValueIndustryS&P 500US Markets
8.71B
80.00
-4.44
-4.94
Earnings HistoryEstimateReportedSurprise %
Q04 20201.851.67-9.73
Q03 20201.491.8020.81
Q02 20201.291.9551.16
Q01 20201.461.8325.34
Q04 20191.661.8612.05
Q03 20191.231.5324.39
Q02 20191.101.2210.91
Q01 20190.950.91-4.21
Earnings Per EndEstimateRevision %Trend
3/2021 QR1.79-7.25Negative
6/2021 QR2.060.98Positive
12/2021 FY8.280.24Positive
12/2022 FY9.32-1.17Negative
Next Report Date4th May 2021
Estimated EPS Next Report1.79
Estimates Count5
EPS Growth Next 5 Years %11.50
Volume Overview
Volume132.32K
Shares Outstanding109.40M
Trades Count1.77K
Dollar Volume78.18M
Avg. Volume761.64K
Avg. Weekly Volume624.38K
Avg. Monthly Volume702.74K
Avg. Quarterly Volume771.54K

DaVita Inc. (NYSE: DVA) stock closed at 109.85 per share at the end of the most recent trading day (a 1.5% change compared to the prior day closing price) with a volume of 764.28K shares and market capitalization of 12.22B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 67000 people. DaVita Inc. CEO is Javier J. Rodriguez.

The one-year performance of DaVita Inc. stock is 45.44%, while year-to-date (YTD) performance is -6.43%. DVA stock has a five-year performance of 48.03%. Its 52-week range is between 71.7 and 125.28, which gives DVA stock a 52-week price range ratio of 74.69%

DaVita Inc. currently has a PE ratio of 17.00, a price-to-book (PB) ratio of 8.41, a price-to-sale (PS) ratio of 1.37, a price to cashflow ratio of 6.60, a PEG ratio of 2.32, a ROA of 4.32%, a ROC of 8.41% and a ROE of 41.75%. The company’s profit margin is 8.04%, its EBITDA margin is 19.50%, and its revenue ttm is $8.71 Billion , which makes it $80.00 revenue per share.

Of the last four earnings reports from DaVita Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.79 for the next earnings report. DaVita Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for DaVita Inc. is Moderate Buy (2.25), with a target price of $132.67, which is +18.99% compared to the current price. The earnings rating for DaVita Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

DaVita Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

DaVita Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.34, ATR14 : 3.11, CCI20 : 84.08, Chaikin Money Flow : -0.02, MACD : -0.44, Money Flow Index : 55.69, ROC : -0.18, RSI : 54.01, STOCH (14,3) : 81.82, STOCH RSI : 0.95, UO : 46.44, Williams %R : -18.18), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of DaVita Inc. in the last 12-months were: Barbara J. Desoer (Option Excercise at a value of $260 153), Barbara J. Desoer (Sold 1 388 shares of value $154 068 ), Charles G. Berg (Option Excercise at a value of $759 999), Charles G. Berg (Sold 714 shares of value $62 498 ), John M. Nehra (Buy at a value of $461 188), John M. Nehra (Option Excercise at a value of $759 999), Kathleen Alyce Waters (Sold 10 000 shares of value $1 050 129 ), Kent J. Thiry (Option Excercise at a value of $10 975 269), Kent J. Thiry (Sold 129 390 shares of value $10 491 928 ), Leanne M. Zumwalt (Option Excercise at a value of $2 680 720), Leanne M. Zumwalt (Sold 3 772 shares of value $332 031 ), Michael David Staffieri (Option Excercise at a value of $7 443 003), Michael David Staffieri (Sold 25 000 shares of value $2 743 515 ), Pamela M. Arway (Option Excercise at a value of $2 089 922), Pamela M. Arway (Sold 11 260 shares of value $1 169 402 ), Paul J. Diaz (Option Excercise at a value of $2 089 922), Paul J. Diaz (Sold 11 526 shares of value $947 650 ), Peter T. Grauer (Option Excercise at a value of $4 994 936), R. Ted Weschler (Sold 2 200 000 shares of value $193 600 000 ), William L. Roper (Option Excercise at a value of $759 999), William L. Roper (Sold 714 shares of value $61 967 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (37.50 %)
3 (37.50 %)
3 (37.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (62.50 %)
5 (62.50 %)
5 (62.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.25
Moderate Buy
2.25
Moderate Buy
2.25

DaVita Inc.

DaVita is the largest provider of dialysis services in the United States, boasting a market share that eclipses 35% when measured by both patients and clinics. The firm operates about 3,000 facilities worldwide, mostly in the U.S., and treats over 235,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

CEO: Javier J. Rodriguez

Telephone: +1 720 631-2100

Address: 2000 16th Street, Denver 80202, CO, US

Number of employees: 67 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

45%55%

Bearish Bullish

50%50%

Bearish Bullish

61%39%

News

Stocktwits